调研纪要：益方生物介绍了多个在研药物的最新进展。D-2570计划用于多个自身免疫性疾病的临床探 索，溃疡性结肠炎II期临床试验已开始。格索雷塞片(商品名称安方宁?)已于2024年11月获得国家药品监 督管理局批准上市，适用于治疗至少接受过一种系统性治疗的KRS G12C突变型的晚期非小细胞肺癌 (NSCLC)成人患者，多项临床研究正在进行。D-0502正在国内和国际进行III期临床试验，初步显示良好 安全性和抗肿瘤效果。D-0120完成IIb期临床试验，YF087和YF550的临床前研究取得进展。 证券之星消息，根据市场公开信息及7月29日披露的机构调研信息，鑫元基金近期对1家上市公司进行了 调研，相关名单如下： 1)益方生物(鑫元基金参与公司特定对象调研) 鑫元基金成立于2013年，截至目前，资产管理规模(全部公募基金)2123.27亿元，排名35/210；资产管理 规模(非货币公募基金)1406.43亿元，排名35/210；管理公募基金数162只，排名47/210；旗下公募基金经 理22人，排名63/210。旗下最近一年表现最佳的公募基金产品为鑫元国证2000指数增强A，最新单位净 值为1.23，近一年增 ...

Group 1 - Penghua Fund recently conducted research on Yifang Biotechnology, discussing the latest progress of several investigational drugs [1] - D-2570 is planned for clinical exploration in multiple autoimmune diseases, with Phase II clinical trials for ulcerative colitis already initiated [1] - Gexuolei Tablets (brand name Anfangning) received approval from the National Medical Products Administration for market launch in November 2024, targeting adult patients with advanced non-small cell lung cancer (NSCLC) who have undergone at least one systemic treatment and have KRS G12C mutations [1] - D-0502 is undergoing Phase III clinical trials both domestically and internationally, showing promising safety and anti-tumor effects [1] - D-0120 has completed Phase IIb clinical trials, while YF087 and YF550 have made progress in preclinical studies [1] Group 2 - As of now, Penghua Fund has an asset management scale of 943.385 billion yuan, ranking 10th out of 210 [2] - The asset management scale for non-monetary public funds is 492.335 billion yuan, also ranking 10th out of 210 [2] - The fund manages 691 public funds, ranking 8th out of 210, with 83 public fund managers, ranking 11th out of 210 [2] - The best-performing public fund product in the past year is Penghua Carbon Neutrality Theme Mixed A, with a latest net value of 1.57 and a growth of 137.71% over the past year [2]